Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has granted 18,600 restricted stock units (RSUs) to a new non-executive employee. The grant, approved by the company's Compensation Committee, was made under the Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually on each grant date anniversary, contingent on continuous employment.
Fate Therapeutics (NASDAQ: FATE), un'azienda biofarmaceutica in fase clinica focalizzata su immunoterapie cellulari derivate da iPSC, ha concesso 18.600 unità azionarie vincolate (RSU) a un nuovo dipendente non esecutivo. La concessione, approvata dal Comitato per la Remunerazione dell'azienda, è stata effettuata nell'ambito del Piano di Induzione azionaria modificato e ripristinato, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4). Le RSU matureranno in quattro anni, con il 25% che matura annualmente in corrispondenza dell'anniversario della data di concessione, a condizione di un impiego continuativo.
Fate Therapeutics (NASDAQ: FATE), una compañía biofarmacéutica en etapa clínica centrada en inmunoterapias celulares derivadas de iPSC, ha otorgado 18,600 unidades de acciones restringidas (RSUs) a un nuevo empleado no ejecutivo. La concesión, aprobada por el Comité de Compensación de la empresa, se realizó bajo el Plan de Inducción de Capital Modificado y Restablecido, de acuerdo con la Regla de Listado Nasdaq 5635(c)(4). Las RSUs se consolidarán durante cuatro años, con un 25% consolidándose anualmente en cada aniversario de la fecha de concesión, sujeto a la continuidad del empleo.
Fate Therapeutics (NASDAQ: FATE), iPSC 유래 세포 면역 요법에 중점을 둔 임상 단계의 생명공학 회사가 새로운 비임원 직원에게 18,600 개의 제한주식 단위 (RSUs)를 부여했습니다. 이 부여는 회사의 보상위원회에서 승인되었으며, Nasdaq 상장 규정 5635(c)(4)에 따라 수정되고 재설정된 유도 주식 계획 하에 이루어졌습니다. RSUs는 4년에 걸쳐 발생하게 되며, 각 부여일 기념일마다 연간 25%가 발생하며, 이는 계속적인 고용에 따라 달라집니다.
Fate Therapeutics (NASDAQ: FATE), une entreprise biopharmaceutique en phase clinique spécialisée dans les immunothérapies cellulaires dérivées d'iPSC, a accordé 18 600 unités d'actions restreintes (RSUs) à un nouvel employé non exécutif. L'octroi, approuvé par le Comité de Rémunération de l'entreprise, a été réalisé dans le cadre du Plan d'Incitation en Capital Modifié et Révisé conformément à la Règle de Cotation Nasdaq 5635(c)(4). Les RSUs s'acquitteront sur quatre ans, avec 25% s'acquittant annuellement à chaque anniversaire de la date d'octroi, sous réserve d'un emploi continu.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf iPSC-abgeleitete Zelltherapien konzentriert, hat einem neuen nicht-executiven Mitarbeiter 18.600 Restricted Stock Units (RSUs) gewährt. Die Gewährung, die vom Vergütungsausschuss des Unternehmens genehmigt wurde, erfolgte im Rahmen des geänderten und neu gefassten Anreizkapitalplans gemäß Nasdaq-Listing-Regel 5635(c)(4). Die RSUs werden über vier Jahre hinweg fällig, wobei 25% jährlich am Jahrestag des Gewährungsdatums fällig werden, vorausgesetzt, das Arbeitsverhältnis besteht fort.
- None.
- None.
SAN DIEGO, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on December 2, 2024 the Company granted restricted stock units (RSUs) representing 18,600 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
How many RSUs did Fate Therapeutics (FATE) grant to its new employee in December 2024?
What is the vesting schedule for FATE's December 2024 employee RSU grant?
Under which rule did Fate Therapeutics (FATE) issue the December 2024 RSU grant?
